A pilot trial of the microtubule-interacting peptide (NAP) in mice overexpressing alpha-synuclein shows improvement in motor function and reduction of alpha-synuclein inclusions.

Fleming SM, Mulligan CK, Richter F, Mortazavi F, Lemesre V, Frias C, Zhu C, Stewart A, Gozes I, Morimoto B, Chesselet MF

Molecular and cellular neurosciences27 Dec 2010Cited by 62 (Europe PMC)

PMID21193046PMCIDPMC3046337DOI10.1016/j.mcn.2010.12.011PepBankPUB-21193046

Source link PubMedAsk about this study

Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In Thy1-aSyn mice, NAP decreased beam traversal errors per step by 38% versus vehicle.
In plain wordsIn mice, NAP reduced beam walking errors by 38% compared with vehicle.
Peptide
Davunetide
Outcome
DecreaseBeam traversal errors per step
Study
mousen: not reported in source
Thy1-aSyn mice
Comparator
Vehicle-treated transgenic mice
Outcome group
Exercise and physical function · Nervous system and cognition
Studied dose
Dose not stated · intranasal · 2 monthsAs given in this study (mouse).
Measurements
Decrease in errors per step
38%
NAP versus vehicle
Source sentences
Summary
NAP-treated Thy1-aSyn mice showed a 38% decrease in the number of errors per step in the challenging beam traversal test and a reduction in proteinase K-resistant α-synuclein inclusions in the substantia nigra compared to vehicle treated transgenics.
1 context sentence(design, population, supporting numbers)
Summary · context
mice overexpressing human wildtype α-synuclein under the Thy1 promoter (Thy1-aSyn) and littermate wildtype control mice were administered daily the microtubule-interacting peptide NAPVSIPQ (NAP; also known as davunetide or AL-108) intranasally for 2 months starting at 1 month of age
Report a problemFND-2119304601
02AnimalAnimal study (in vivo)Mechanism
In Thy1-aSyn mice, NAP reduced proteinase K-resistant alpha-synuclein inclusions in the substantia nigra versus vehicle.
In plain wordsIn mice, NAP reduced resistant alpha-synuclein deposits in the substantia nigra compared with vehicle.
Peptide
Davunetide
Outcome
DecreaseSubstantia nigra alpha-synuclein inclusions
Study
mousen: not reported in source
Thy1-aSyn mice
Comparator
Vehicle-treated transgenic mice
Outcome group
Neuroprotection · Nervous system and cognition
Studied dose
Dose not stated · intranasal · 2 monthsAs given in this study (mouse).
Source sentences
Summary
NAP-treated Thy1-aSyn mice showed a 38% decrease in the number of errors per step in the challenging beam traversal test and a reduction in proteinase K-resistant α-synuclein inclusions in the substantia nigra compared to vehicle treated transgenics.
1 context sentence(design, population, supporting numbers)
Summary · context
mice overexpressing human wildtype α-synuclein under the Thy1 promoter (Thy1-aSyn) and littermate wildtype control mice were administered daily the microtubule-interacting peptide NAPVSIPQ (NAP; also known as davunetide or AL-108) intranasally for 2 months starting at 1 month of age
Report a problemFND-2119304602

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
27 Oct 2026, 18:20 UTC
Study results updated
Version 1
27 Oct 2026, 16:32 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.